Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Revenue (2022 - 2025)

Taysha Gene Therapies' Revenue history spans 4 years, with the latest figure at $2.0 million for Q2 2025.

  • For Q2 2025, Revenue rose 78.6% year-over-year to $2.0 million; the TTM value through Sep 2025 reached $6.3 million, down 36.36%, while the annual FY2024 figure was $8.3 million, 46.07% down from the prior year.
  • Revenue for Q2 2025 was $2.0 million at Taysha Gene Therapies, down from $2.3 million in the prior quarter.
  • Across five years, Revenue topped out at $4.7 million in Q3 2023 and bottomed at -$2.5 million in Q3 2022.
  • The 4-year median for Revenue is $2.0 million (2024), against an average of $1.6 million.
  • The largest annual shift saw Revenue soared 800.3% in 2023 before it crashed 62.33% in 2024.
  • A 4-year view of Revenue shows it stood at -$1.3 million in 2022, then surged by 376.17% to $3.6 million in 2023, then tumbled by 43.9% to $2.0 million in 2024, then decreased by 1.78% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Revenue are $2.0 million (Q2 2025), $2.3 million (Q1 2025), and $2.0 million (Q4 2024).